BATF2 reverses multidrug resistance of human gastric cancer cells by suppressing Wnt/β-catenin signaling

  • Wei Yang
  • Bian Wu
  • Ning Ma
  • Yongfang Wang
  • Jianhui Guo
  • Jun Zhu
  • Sihui ZhaoEmail author


Gastric cancer (GC) is a commonly occurring neoplasm worldwide. The occurrence of multidrug resistance (MDR) in GC cells is the main obstacle to effective GC chemotherapy. The aim of the present study was to reveal the functional role and the underlying mechanisms of basic leucine zipper ATF-like transcription factor 2 (BATF2), a novel tumor suppressor, on MDR in GC cells. Here, we first found that SGC7901/VCR and SGC7901/ADR cells had higher drug resistance than SGC7901 cells using methylthiazol tetrazolium (MTT) and flow cytometry analysis. Moreover, MDR-related proteins and Wnt/β-catenin pathway markers were all upregulated in SGC7901/VCR cells compared to SGC7901 cells by quantitative reverse transcription-PCR (qRT-PCR) and western blot analyses. Subsequently, we observed BATF2 was downregulated in SGC7901/VCR cells and BATF2 overexpression significantly induced cell cycle G0/G1 phase arrest and apoptosis. Furthermore, overexpression of BATF2 could suppress Wnt/β-catenin signaling and increase drug susceptibility by downregulating Wnt/β-catenin pathway markers. In addition, knockdown of β-catenin imitated the effects of BATF2 overexpression on drug susceptibility. Importantly, enhancing the Wnt/β-catenin pathway could reverse the inhibitory effects of BATF2 on MDR. In conclusion, BATF2 was downregulated in MDR GC cells and overexpression of BATF2 could reverse the MDR of GC cells by inactivating the Wnt/β-catenin pathway.


Gastric cancer Multidrug resistance BATF2 Wnt/β-catenin pathway 



This study was supported by the applied Basic Research Joint Fund Project of Yunnan Provincial Science and Technology Department-Kunming Medical University (Grant No. 2017FE468(-108), 2015FB099) and Scientific Research Fund Project of Yunnan Provincial Education Department (Grant No. 2016ZDX020).

Compliance with ethical standards

Competing interests

The authors declare that they have no competing interests.


  1. Borst P, Evers R, Kool M, Wijnholds J (2000) A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295–1302CrossRefGoogle Scholar
  2. Bray F, Ren JS, Masuyer E, Ferlay J (2013) Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 132:1133–1145CrossRefGoogle Scholar
  3. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66:115–132CrossRefGoogle Scholar
  4. Dai L, Cui X, Zhang X, Cheng L, Liu Y, Yang Y, Fan P, Wang Q, Lin Y, Zhang J, Li C, Mao Y, Wang Q, Su X, Zhang S, Peng Y, Yang H, Hu X, Yang J, Huang M, Xiang R, Yu D, Zhou Z, Wei Y, Deng H (2016) SARI inhibits angiogenesis and tumour growth of human colon cancer through directly targeting ceruloplasmin. Nat Commun 7:11996CrossRefGoogle Scholar
  5. Dash R, Su ZZ, Lee SG, Azab B, Boukerche H, Sarkar D, Fisher PB (2010) Inhibition of AP-1 by SARI negatively regulates transformation progression mediated by CCN1. Oncogene 29:4412–4423CrossRefGoogle Scholar
  6. Eom BW, Kim S, Kim JY, Yoon HM, Kim MJ, Nam BH, Kim YW, Park YI, Park SR, Ryu KW (2018) Survival benefit of perioperative chemotherapy in patients with locally advanced gastric cancer: a propensity score matched analysis. J Gastric Cancer 18:69–81CrossRefGoogle Scholar
  7. Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, Negri E, La Vecchia C, Lunet N (2014) Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype. Eur J Cancer 50:1330–1344CrossRefGoogle Scholar
  8. Fodale V, Pierobon M, Liotta L, Petricoin E (2011) Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance? Cancer J 17:89–95CrossRefGoogle Scholar
  9. Gillet JP, Efferth T, Remacle J (2007) Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 1775:237–262Google Scholar
  10. Guler R, Roy S, Suzuki H, Brombacher F (2015) Targeting Batf2 for infectious diseases and cancer. Oncotarget 6:26575–26582CrossRefGoogle Scholar
  11. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW (1998) Identification of c-MYC as a target of the APC pathway. Science 281:1509–1512CrossRefGoogle Scholar
  12. Huang W, Zhang C, Cui M, Niu J, Ding W (2017) Inhibition of bevacizumab-induced epithelial-mesenchymal transition by BATF2 overexpression involves the suppression of Wnt/beta-catenin signaling in glioblastoma cells. Anticancer Res 37:4285–4294Google Scholar
  13. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300CrossRefGoogle Scholar
  14. Kageji T, Obata F, Oka H, Kanematsu Y, Tabata R, Tani K, Bando H, Nagahiro S (2016) Drip-and-ship thrombolytic therapy supported by the telestroke system for acute ischemic stroke patients living in medically under-served areas. Neurol Med Chir 56:753–758CrossRefGoogle Scholar
  15. Klaus A, Birchmeier W (2008) Wnt signalling and its impact on development and cancer. Nat Rev Cancer 8:387–398CrossRefGoogle Scholar
  16. Komiya S, Gebhardt MC, Mangham DC, Inoue A (1998) Role of glutathione in cisplatin resistance in osteosarcoma cell lines. J Orthop Res 16:15–22CrossRefGoogle Scholar
  17. Lim JC, Kania KD, Wijesuriya H, Chawla S, Sethi JK, Pulaski L, Romero IA, Couraud PO, Weksler BB, Hladky SB, Barrand MA (2008) Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem 106:1855–1865Google Scholar
  18. Liu Z, Wei P, Yang Y, Cui W, Cao B, Tan C, Yu B, Bi R, Xia K, Chen W, Wang Y, Zhang Y, Du X, Zhou X (2015) BATF2 deficiency promotes progression in human colorectal cancer via activation of HGF/MET signaling: a potential rationale for combining MET inhibitors with IFNs. Clin Cancer Res 21:1752–1763CrossRefGoogle Scholar
  19. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25:402–408CrossRefGoogle Scholar
  20. Lutz MP, Zalcberg JR, Ducreux M, Ajani JA, Allum W, Aust D, Bang YJ, Cascinu S, Holscher A, Jankowski J, Jansen EP, Kisslich R, Lordick F, Mariette C, Moehler M, Oyama T, Roth A, Rueschoff J, Ruhstaller T, Seruca R, Stahl M, Sterzing F, van Cutsem E, van der Gaast A, van Lanschot J, Ychou M, Otto F, First St Gallen EGCCEP (2012) Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer—differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer 48:2941–2953CrossRefGoogle Scholar
  21. MacDonald BT, Tamai K, He X (2009) Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 17:9–26CrossRefGoogle Scholar
  22. Rugge M, Genta RM, Di Mario F, El-Omar EM, El-Serag HB, Fassan M, Hunt RH, Kuipers EJ, Malfertheiner P, Sugano K, Graham DY (2017) Gastric cancer as preventable disease. Clin Gastroenterol Hepatol 15:1833–1843CrossRefGoogle Scholar
  23. Shen DY, Zhang W, Zeng X, Liu CQ (2013) Inhibition of Wnt/beta-catenin signaling downregulates P-glycoprotein and reverses multi-drug resistance of cholangiocarcinoma. Cancer Sci 104:1303–1308CrossRefGoogle Scholar
  24. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo JA, Golub TR (2012) Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487:500–504CrossRefGoogle Scholar
  25. Su ZZ, Lee SG, Emdad L, Lebdeva IV, Gupta P, Valerie K, Sarkar D, Fisher PB (2008) Cloning and characterization of SARI (suppressor of AP-1, regulated by IFN). Proc Natl Acad Sci U S A 105:20906–20911CrossRefGoogle Scholar
  26. Sun YL, Patel A, Kumar P, Chen ZS (2012) Role of ABC transporters in cancer chemotherapy. Chin J Cancer 31:51–57CrossRefGoogle Scholar
  27. Tetsu O, McCormick F (1999) Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398:422–426CrossRefGoogle Scholar
  28. Tussiwand R, Lee WL, Murphy TL, Mashayekhi M, Kc W, Albring JC, Satpathy AT, Rotondo JA, Edelson BT, Kretzer NM, Wu X, Weiss LA, Glasmacher E, Li P, Liao W, Behnke M, Lam SS, Aurthur CT, Leonard WJ, Singh H, Stallings CL, Sibley LD, Schreiber RD, Murphy KM (2012) Compensatory dendritic cell development mediated by BATF-IRF interactions. Nature 490:502–507CrossRefGoogle Scholar
  29. Valenta T, Hausmann G, Basler K (2012) The many faces and functions of beta-catenin. EMBO J 31:2714–2736CrossRefGoogle Scholar
  30. Van Cutsem E, Dicato M, Geva R, Arber N, Bang Y, Benson A, Cervantes A, Diaz-Rubio E, Ducreux M, Glynne-Jones R, Grothey A, Haller D, Haustermans K, Kerr D, Nordlinger B, Marshall J, Minsky BD, Kang YK, Labianca R, Lordick F, Ohtsu A, Pavlidis N, Roth A, Rougier P, Schmoll HJ, Sobrero A, Tabernero J, Van de Velde C, Zalcberg J (2011) The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. Ann Oncol 22(Suppl 5):v1–v9CrossRefGoogle Scholar
  31. Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H (2016) Gastric cancer. Lancet 388:2654–2664CrossRefGoogle Scholar
  32. Wang C, Su Y, Zhang L, Wang M, You J, Zhao X, Zhang Z, Liu J, Hao X (2012) The function of SARI in modulating epithelial-mesenchymal transition and lung adenocarcinoma metastasis. PLoS One 7:e38046CrossRefGoogle Scholar
  33. Wang QW, Zhang XT, Lu M, Shen L (2018) Impact of duration of adjuvant chemotherapy in radically resected patients with T4bN1-3M0/TxN3bM0 gastric cancer. World J Gastrointestin Oncol 10:31–39CrossRefGoogle Scholar
  34. Yeh KH, Shun CT, Chen CL, Lin JT, Lee WJ, Lee PH, Chen YC, Cheng AL (1999) Overexpression of p53 is not associated with drug resistance of gastric cancers to 5-fluorouracil-based systemic chemotherapy. Hepato-gastroenterology 46:610–615Google Scholar
  35. Yuan Z, Shi X, Qiu Y, Jia T, Yuan X, Zou Y, Liu C, Yu H, Yuan Y, He X, Xu K, Yin P (2017) Reversal of P-gp-mediated multidrug resistance in colon cancer by cinobufagin. Oncol Rep 37:1815–1825CrossRefGoogle Scholar
  36. Zhang ZY, Ge HY (2013) Micrometastasis in gastric cancer. Cancer Lett 336:34–45CrossRefGoogle Scholar
  37. Zhang H, Zhang X, Wu X, Li W, Su P, Cheng H, Xiang L, Gao P, Zhou G (2012) Interference of Frizzled 1 (FZD1) reverses multidrug resistance in breast cancer cells through the Wnt/beta-catenin pathway. Cancer Lett 323:106–113CrossRefGoogle Scholar
  38. Zhang WH, Song XH, Chen XZ, Yang K, Liu K, Chen ZX, Zhou ZG, Hu JK (2018) Characteristics and survival outcomes related to the infra-pyloric lymph node status of gastric cancer patients. World J Surg Oncol 16:116CrossRefGoogle Scholar
  39. Zheng R, Zeng H, Zhang S, Chen W (2017) Estimates of cancer incidence and mortality in China, 2013. Chin J Cancer 36:66CrossRefGoogle Scholar

Copyright information

© The Society for In Vitro Biology 2019

Authors and Affiliations

  • Wei Yang
    • 1
    • 2
  • Bian Wu
    • 1
    • 2
  • Ning Ma
    • 1
    • 2
  • Yongfang Wang
    • 1
    • 2
  • Jianhui Guo
    • 1
    • 2
  • Jun Zhu
    • 1
    • 2
  • Sihui Zhao
    • 1
    • 2
    Email author
  1. 1.Second Department of General Surgerythe First People’s Hospital of Yunnan ProvinceKunmingChina
  2. 2.The Affiliated Hospital of Kunming University of Science and TechnologyKunmingChina

Personalised recommendations